BioLargo Files 8-K Report

Ticker: BLGO · Form: 8-K · Filed: Jun 13, 2024 · CIK: 880242

Sentiment: neutral

Topics: 8-K, filing, disclosure

Related Tickers: BLGO

TL;DR

BioLargo filed an 8-K, likely containing updates for investors.

AI Summary

On June 13, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt of the filing.

Why It Matters

This 8-K filing indicates BioLargo, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided excerpt is a standard 8-K filing notification and does not contain specific financial or operational details that would indicate a high-risk event.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by BioLargo, Inc.?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the filing details.

When was this 8-K report filed?

The report was filed on June 13, 2024.

In which state is BioLargo, Inc. incorporated?

BioLargo, Inc. is incorporated in Delaware.

What is the principal executive office address for BioLargo, Inc.?

The principal executive office is located at 14921 Chestnut St., Westminster, California 92683.

Does this filing excerpt detail any specific financial results or new business developments?

No, the provided excerpt of the 8-K filing does not detail specific financial results or new business developments.

Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-06-13 14:34:19

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. BioLargo, Inc., intends to present the slides attached as Exhibit 99.1 , which are incorporated herein by reference, at its annual stockholder meeting on June 13, 2024, at 10:00 am Pacific Time. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the presentation slides attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading "Safe Harbor Act" in Exhibit 99.1 attached hereto.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Presentation slides 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 13, 2024 BIOLARGO, INC. By: /s/ Dennis P. Calvert Dennis P. Calvert President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing